Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond Schuch

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Diagnostic Microbiology and Infectious Disease|August 31, 2019
In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015-2017Maria Traczewski, Jun Oh, Cara Cassino, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2019
Exebacase Demonstrates <i>In Vitro</i> Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureusAubrey Watson, Karen Sauve, Cara Cassino, et al.
Applied and Environmental Microbiology|September 21, 2010
Identifying active phage lysins through functional viral metagenomicsJonathan E Schmitz, Raymond Schuch, Vincent A Fischetti
Journal of Clinical Microbiology|April 29, 2021
Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal ActivityMaria M Traczewski, Jane E Ambler, Raymond Schuch
Methods in Molecular Biology (Clifton, N.J.)|December 17, 2008
A genetic screen to identify bacteriophage lysinsRaymond Schuch, Vincent A Fischetti, Daniel C Nelson
Antimicrobial Agents and Chemotherapy|July 6, 2021
Exebacase Is Active <i>In Vitro</i> in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung InfectionSteven M Swift, Karen Sauve, Cara Cassino, et al.
Journal of Bacteriology|July 30, 2013
Identification of a ligand on the Wip1 bacteriophage highly specific for a receptor on Bacillus anthracisSherry Kan, Nadine Fornelos, Raymond Schuch, et al.
Journal of Bacteriology|July 3, 2004
Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faeciumPauline Yoong, Raymond Schuch, Daniel Nelson, et al.
Journal of Bacteriology|March 21, 2006
PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracisPauline Yoong, Raymond Schuch, Daniel Nelson, et al.
Microbiology Spectrum|March 2, 2023
The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal AntibioticsJun Oh, Matthew Warner, Jane E Ambler, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Diagnostic Microbiology and Infectious Disease|August 31, 2019
In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015-2017Maria Traczewski, Jun Oh, Cara Cassino, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2019
Exebacase Demonstrates <i>In Vitro</i> Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureusAubrey Watson, Karen Sauve, Cara Cassino, et al.
Applied and Environmental Microbiology|September 21, 2010
Identifying active phage lysins through functional viral metagenomicsJonathan E Schmitz, Raymond Schuch, Vincent A Fischetti
Journal of Clinical Microbiology|April 29, 2021
Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal ActivityMaria M Traczewski, Jane E Ambler, Raymond Schuch
Methods in Molecular Biology (Clifton, N.J.)|December 17, 2008
A genetic screen to identify bacteriophage lysinsRaymond Schuch, Vincent A Fischetti, Daniel C Nelson
Antimicrobial Agents and Chemotherapy|July 6, 2021
Exebacase Is Active <i>In Vitro</i> in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung InfectionSteven M Swift, Karen Sauve, Cara Cassino, et al.
Journal of Bacteriology|July 30, 2013
Identification of a ligand on the Wip1 bacteriophage highly specific for a receptor on Bacillus anthracisSherry Kan, Nadine Fornelos, Raymond Schuch, et al.
Journal of Bacteriology|July 3, 2004
Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faeciumPauline Yoong, Raymond Schuch, Daniel Nelson, et al.
Journal of Bacteriology|March 21, 2006
PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracisPauline Yoong, Raymond Schuch, Daniel Nelson, et al.
Microbiology Spectrum|March 2, 2023
The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal AntibioticsJun Oh, Matthew Warner, Jane E Ambler, et al.
Pageof 6